Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNATE SODIUM vs ATROMID-S
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema,Off-label: Adjunct in treatment of acute hypercalcemia
Type III hyperlipoproteinemia,Hypertriglyceridemia (Fredrickson types IV and V) not responsive to diet
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Primarily metabolized by hepatic glutathione S-transferase (GST) to a cysteine conjugate; minor metabolism via oxidation. Excreted in urine and bile.
Hepatic via glucuronidation and oxidation; major metabolite is clofibric acid.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Approximately 95% bound, primarily to albumin.
>95% bound to plasma proteins, primarily albumin.
0.1-0.2 L/kg (small Vd, consistent with high protein binding and limited extravascular distribution).
0.11-0.14 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral: approximately 100% (well absorbed, no significant first-pass metabolism).
Oral: approximately 60-70% due to first-pass metabolism; administered as clofibrate (prodrug) which is hydrolyzed to active clofibric acid.
e GFR 30-59 m L/min: reduce dose by 50%; e GFR <30 m L/min: avoid use or use with extreme caution.
GFR 30-59 m L/min: 500 mg twice daily. GFR 15-29 m L/min: 250 mg twice daily. GFR <15 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class B or C: avoid use or reduce dose by at least 50%; not recommended in severe hepatic impairment.
1 mg/kg intravenously once daily; maximum 50 mg/day. Not recommended in neonates.
Not recommended; safety and efficacy not established in pediatric patients.
Start at 25 mg intravenously once daily; increase slowly due to increased risk of electrolyte disturbances and hypotension.
Start at lower end of dosing range (500 mg twice daily). Monitor renal function; adjust dose based on GFR.
Ethacrynic acid (ethacrynate) can cause profound diuresis with water and electrolyte depletion; close medical supervision and dose titration are required.
None
May cause severe electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) and volume depletion,Ototoxicity, especially with rapid IV administration or in patients with renal impairment; may be irreversible,Hyperuricemia and gout,Hepatic coma can be precipitated in patients with cirrhosis or ascites,May increase risk of digoxin toxicity due to hypokalemia,Photosensitivity reaction possible
Hepatotoxicity,Cholelithiasis,Renal impairment dose adjustment,Rhabdomyolysis risk with statins,Malignancy risk (hepatic, GI)
Anuria,Hypersensitivity to ethacrynic acid or any component,Severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Hepatic coma or precoma
Hypersensitivity to clofibrate,Active liver disease,Severe renal dysfunction,Primary biliary cirrhosis,Pregnancy
Avoid excessive intake of salt substitutes containing potassium unless advised by your doctor. Grapefruit juice may enhance diuretic effect; monitor for hypotension. Alcohol can increase diuretic effect and risk of hypotension. Caffeine may worsen electrolyte imbalance. Ensure adequate fluid intake unless fluid restriction is prescribed.
High-fat meals may reduce absorption; consistent timing of administration with food is recommended. Grapefruit juice may increase drug levels; avoid excessive intake. Alcohol may exacerbate hepatotoxicity.
Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, ototoxicity, and oligohydramnios in the fetus due to diuretic effect. Avoid use in pregnancy unless clearly needed.
FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit outweighs risk. Second and third trimesters: May cause fetal harm due to placental transfer and potential for reduced fetal growth.
Excreted into breast milk in low concentrations; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., electrolyte imbalance, diuresis). Weigh benefits against risks; consider alternative diuretics.
Excreted into breast milk in low amounts; M/P ratio not established. Due to potential for serious adverse effects in infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, specific dose adjustments for ethacrynate sodium are not established. Use lowest effective dose and monitor for hypotension and electrolyte imbalances.
No specific dosing adjustments recommended due to lack of data. However, pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may necessitate careful monitoring and empiric dose adjustments based on clinical response and adverse effects.
Ethacrynate sodium is a loop diuretic used for patients with sulfonamide allergy as it is not a sulfonamide derivative. Monitor for ototoxicity, especially in patients with renal impairment or when used with other ototoxic drugs. Rapid IV administration can cause severe hypotension; infuse slowly over several minutes. Hypokalemia and hypomagnesemia are common; monitor electrolytes and consider potassium-sparing diuretic or supplementation. Ethacrynic acid can cause GI bleeding; use with caution in peptic ulcer disease.
ATROMID-S (clofibrate) is a fibric acid derivative primarily indicated for hyperlipidemia but its use is now limited due to increased non-cardiovascular mortality and cholelithiasis risk. Monitor liver function and prothrombin time (potentiates warfarin). Not first-line; consider statins or fibrates like fenofibrate.
Take this medication exactly as prescribed, usually once or twice daily.,You may need to urinate frequently; take your last dose of the day early to avoid nighttime urination.,Avoid alcohol and limit salt intake to help reduce fluid retention.,Report any hearing loss, ringing in the ears, or dizziness to your healthcare provider immediately.,Eat potassium-rich foods like bananas, oranges, or potatoes unless directed otherwise by your doctor.,Weigh yourself daily and report sudden weight gain or loss to your healthcare provider.,Do not take any over-the-counter medications, especially NSAIDs, without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
Take with meals to reduce gastrointestinal upset.,Report unexplained muscle pain, tenderness, or weakness; may indicate myopathy.,Avoid alcohol as it may increase liver enzyme elevations.,Notify your doctor if you develop gallstones symptoms (e.g., right upper abdominal pain, nausea).,Use effective contraception as clofibrate may cause fetal harm.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNATE SODIUM vs ATROMID-S, answered by our medical review team.
ETHACRYNATE SODIUM is a Loop Diuretic that works by Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. ATROMID-S is a Antilipemic Agent that works by Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNATE SODIUM and ATROMID-S depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNATE SODIUM is: 50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.. The standard adult dose of ATROMID-S is: 500 mg to 1 g orally twice daily. Maximum dose 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNATE SODIUM and ATROMID-S in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNATE SODIUM is classified as Category C. Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, oto. ATROMID-S is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for teratogenicity based on animal studies showing skeletal and visceral anomalies. Human data limited; use only if benefit out. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.